drugset / Trial / NCT02332655
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Phase 1/2
Completed
5 enrolled
Anne Comi, MD
Faneca 66 Foundation · collabJazz Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome (SWS) and drug resistant epilepsy.
Timeline
- Start
- 2014-12
- Primary completion
- 2019-04
- Completion
- 2021-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 25 mg/kg | Oral |